A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: Analysis of week 144 results

Nathan Clumeck, Jean Michel Molina, Keith Henry, Joseph Gathe, Jürgen K. Rockstroh, Edwin Dejesus, Xuelian Wei, Kirsten White, Marshall W. Fordyce, Martin S. Rhee, Javier Szwarcberg

Research output: Contribution to journalLetterpeer-review

78 Scopus citations
Original languageEnglish (US)
Pages (from-to)e121-e124
JournalJournal of Acquired Immune Deficiency Syndromes
Issue number3
StatePublished - Mar 1 2014

Cite this